This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Oral beclomethasone 17,21-dipropionate (oral BDP), SGX202, oral beclomethasone dipropionate
SGX202 is formulated for oral administration in gastrointestinal acute radiation syndrome (GI ARS) patients as a single product consisting of two tablets; one tablet is intended to release beclomethasone dipropionate (BDP), a glucocorticoid, in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract. Glucocorticoids have potent anti-inflammatory and immunosuppressive properties. This is particularly evident when they are administered at pharmacologic doses, but also is important in normal immune responses. As a consequence, glucocorticoids are widely used as drugs to treat inflammatory conditions such as arthritis or dermatitis, and as adjunction therapy for conditions such as autoimmune diseases.
SGX202 has the potential to reduce the inflammatory cytokine storm induced by the radiation damaged GI tract. The GI tract is extremely sensitive to radiation injury. GI damage is the major cause of rapid mortality during high dose radiation exposure, such as could be encountered during nuclear accidents or with the use of dirty bombs. Gut injury from high dose radiation is associated with epithelial cell damage and hypoperfusion of the intestine, which stimulates a vigorous local and systemic inflammatory response.
Pink Sheet Weekly Trademark Review Jan. 31, 2017
Additional information available to subscribers only: